✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
TRC105 is an investigational drug.
There have been 21 clinical trials for TRC105. The most recent clinical trial was a Phase 3 trial, which was initiated on February 13th 2017.
The most common disease conditions in clinical trials are Carcinoma, Neoplasms, and Carcinoma, Hepatocellular. The leading clinical trial sponsors are Tracon Pharmaceuticals Inc., National Cancer Institute (NCI), and University of Alabama at Birmingham.
There are two US patents protecting this investigational drug and sixty-six international patents.
Recent Clinical Trials for TRC105
|Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer||Enviro Therapeutics, Inc.||Phase 1|
|Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer||Karen Reckamp, MD, MS||Phase 1|
|Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy||Cedars-Sinai Medical Center||Phase 2|
Top disease conditions for TRC105
Top clinical trial sponsors for TRC105
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|TRC105||See Plans and Pricing||Methods of administering IgG1 antibodies and methods of suppressing angiogenesis||University of Kentucky Research Foundation (Lexington, KY)||See Plans and Pricing|
|TRC105||See Plans and Pricing||Posterior segment drug delivery||ForSight Vision4, Inc. (Menlo Park, CA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|TRC105||Canada||CA2907548||2033-03-13||See Plans and Pricing|
|TRC105||European Patent Office||EP2968556||2033-03-13||See Plans and Pricing|
|TRC105||World Intellectual Property Organization (WIPO)||WO2014160336||2033-03-13||See Plans and Pricing|
|TRC105||Australia||AU2010208046||2029-01-29||See Plans and Pricing|
|TRC105||Australia||AU2011285501||2029-01-29||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|